SCHEMBL17508350

SCHEMBL17508350

Clc1cc(-c2ccc(-c3ccccc3)cc2)c2ccccc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACA Q13085 4/20 0.51
EGFR P00533 1/20 0.47
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
KDM4E B2RXH2 4/20 0.44
MAPK1 P28482 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
MAPT P10636 1/20 0.44
GRM2 Q14416 2/20 0.44
USP2 O75604 1/20 0.43
HTT P42858 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
DHODH Q02127 1/20 0.42
AURKA O14965 1/20 0.42
AURKB Q96GD4 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29352882 0.96 ACACA (0.50) ACACAEGFRMAOAMAOBKDM4E
SCHEMBL4083079 0.96 ACACA (0.50) ACACAEGFRMAOAMAOBKDM4E
SCHEMBL10629041 0.91 LTB4R (0.50) ACACAMAOAMAOBKDM4EMAPK1
SCHEMBL17508372 0.89 MAOA (0.42) ACACAEGFRMAOAMAOBKDM4E
SCHEMBL10630879 0.88 GRM2 (0.58) ACACAMAOAMAOBKDM4EALDH1A1
SCHEMBL10627563 0.88 ALDH1A1 (0.55) ACACAKDM4EL3MBTL1ALDH1A1HPGD
SCHEMBL28181895 0.87 PIK3CA (0.51) ACACAKDM4EMAPK1ALDH1A1MAPT
SCHEMBL17508354 0.84 GSTP1 (0.46) ACACAMAOAMAOBKDM4EALDH1A1
SCHEMBL10627554 0.84 LTB4R (0.51) ACACAGRM2
SCHEMBL4607752 0.81 ACACA (0.73) ACACAKDM4EMAPK1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9676767-B2 Indoloacridine-containing derivative, preparation process and use thereof, and organic luminescent device BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-06-13 US disclosed
US-9676767-B2 Indoloacridine-containing derivative, preparation process and use thereof, and organic luminescent device BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-06-13 US disclosed
US-9676767-B2 Indoloacridine-containing derivative, preparation process and use thereof, and organic luminescent device BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-06-13 US disclosed
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE BOE TECHNOLOGY GROUP CO., LTD. (CN) 2016-02-18 US disclosed
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE BOE TECHNOLOGY GROUP CO., LTD. (CN) 2016-02-18 US disclosed
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE BOE TECHNOLOGY GROUP CO., LTD. (CN) 2016-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE AHR, CDYL, SLC18A1 ACACA 3729/4885EGFR 1935/4885MAOA 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.